Cyclacel Ltd.
This article was originally published in Start Up
Executive Summary
With one of the discoverers of p53, David Lane, PhD as its scientific officer, Cyclacel is developing small molecule anti-cancer drugs which target the cell cycle.
You may also be interested in...
British Start-Ups
Many think that British biotech is a disaster waiting to happen. The four companies profiled in this issue are attempting to establish themselves as product-driven companies, run by professional managers.
AureoGen Biosciences Inc.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain Therapeutics
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.